INSM · Insmed Incorporated

The CEDAR study’s failure to demonstrate efficacy—where both brensocatib doses underperformed placebo on the primary endpoint of percent change in abscess and inflammatory nodule (AN) count at Week 16—represents a material setback for Insmed’s dermatology pipeline and eliminates a potential near-term commercial opportunity in hidradenitis suppurativa (HS). The negative outcome is particularly notable given the absence of meaningful efficacy separation from placebo despite robust trial execution: enrollment of 214 patients across 72 global sites, rigorous 1:1:1 randomization, and adherence to a pre-specified 16-week primary analysis window. While safety remained consistent with prior brensocatib studies—including no new signals at the highest dose tested (40 mg)—the lack of clinical benefit outweighs tolerability advantages. Management explicitly characterized CEDAR as a proof-of-concept study, acknowledging the scientific challenges of HS drug development due to limited animal models; however, the discontinuation reflects a decisive strategic pivot away from this indication rather than continuation into further trials. This decision removes future R&D expense associated with HS development but also forfeits any potential regulatory pathway or partnership value tied to brensocatib in dermatology. Investors should note that the company intends to present full data at a future scientific congress, suggesting transparency around the dataset, though no further clinical investment in HS is planned. The announcement carries high materiality because it terminates a late-phase asset in a therapeutic area with high unmet need and no approved oral therapies, narrowing Insmed’s near-term pipeline diversification outside its core pulmonary franchise.